287 related articles for article (PubMed ID: 22182771)
1. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
Koren E; Apte A; Jani A; Torchilin VP
J Control Release; 2012 Jun; 160(2):264-73. PubMed ID: 22182771
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Apte A; Koren E; Koshkaryev A; Torchilin VP
Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
[TBL] [Abstract][Full Text] [Related]
3. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
Sawant RM; Hurley JP; Salmaso S; Kale A; Tolcheva E; Levchenko TS; Torchilin VP
Bioconjug Chem; 2006; 17(4):943-9. PubMed ID: 16848401
[TBL] [Abstract][Full Text] [Related]
4. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes.
Kale AA; Torchilin VP
J Liposome Res; 2007; 17(3-4):197-203. PubMed ID: 18027240
[TBL] [Abstract][Full Text] [Related]
5. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements.
Koren E; Apte A; Sawant RR; Grunwald J; Torchilin VP
Drug Deliv; 2011 Jul; 18(5):377-84. PubMed ID: 21438724
[TBL] [Abstract][Full Text] [Related]
6. Environment-responsive multifunctional liposomes.
Kale AA; Torchilin VP
Methods Mol Biol; 2010; 605():213-42. PubMed ID: 20072884
[TBL] [Abstract][Full Text] [Related]
7. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Elbayoumi TA; Torchilin VP
Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
[TBL] [Abstract][Full Text] [Related]
9. Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.
Biswas S; Dodwadkar NS; Sawant RR; Torchilin VP
Bioconjug Chem; 2011 Oct; 22(10):2005-13. PubMed ID: 21870873
[TBL] [Abstract][Full Text] [Related]
10. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes.
Kale AA; Torchilin VP
J Drug Target; 2007; 15(7-8):538-45. PubMed ID: 17671900
[TBL] [Abstract][Full Text] [Related]
11. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
[TBL] [Abstract][Full Text] [Related]
12. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
Perche F; Patel NR; Torchilin VP
J Control Release; 2012 Nov; 164(1):95-102. PubMed ID: 22974689
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release.
Zhang Y; Xiao Y; Huang Y; He Y; Xu Y; Lu W; Yu J
Colloids Surf B Biointerfaces; 2020 Apr; 188():110772. PubMed ID: 31999965
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
Zhu L; Kate P; Torchilin VP
ACS Nano; 2012 Apr; 6(4):3491-8. PubMed ID: 22409425
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody.
Lukyanov AN; Elbayoumi TA; Chakilam AR; Torchilin VP
J Control Release; 2004 Nov; 100(1):135-44. PubMed ID: 15491817
[TBL] [Abstract][Full Text] [Related]
16. A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy.
Zhang L; Tian B; Li Y; Lei T; Meng J; Yang L; Zhang Y; Chen F; Zhang H; Xu H; Zhang Y; Tang X
ACS Appl Mater Interfaces; 2015 Nov; 7(45):25147-61. PubMed ID: 26501354
[TBL] [Abstract][Full Text] [Related]
17. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
18. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
19. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
